Cincinnati, Ohio
CTI Clinical Trial and Consulting Services (CTI) announces the acquisition of CRS Clinical Research Services and CRS – Staff Leasing Services (CRS), a clinical research organization headquartered in Northern Germany. CTI will incorporate all CRS employees into its current European operations and maintain the CRS headquarters located near Hamburg, Germany. CTI is planning to augment its coverage in Germany with the opening of an additional office in the southern region of the country in the coming months.
CRS is a full service, therapeutically-focused clinical research organization, with an emphasis on phase II and phase III clinical trials. Therapeutic areas of focus include infectious disease, oncology, and autoimmune diseases. CRS has managed clinical trials for large pharmaceutical companies, biotechnology companies, and for non-profit organizations across Western Europe.
“The addition of the CRS management and research teams will significantly advance CTI’s current expansion in Europe,” says Timothy Schroeder, CTI President and CEO.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
The State of the Opioid Epidemic
March 26th 2024In part 1 of this video interview, Greg Sturmer, co-founder and CEO of Elysium Therapeutics discusses the current state of opioid usage including how pain treatment is often mismanaged and how the industry can adopt greater safety standards in developing pain therapies.